论文部分内容阅读
目的对莫沙必利联合埃索美拉唑治疗反流性食管炎的临床疗效进行探究。方法选取184例在本院接受治疗的反流性食管炎患者,将其平均分为实验组和对照组两组,对照组与实验组患者分别采用奥美拉唑联合莫沙必利治疗和埃索美拉唑联合莫沙必利治疗,对两组患者的临床疗效及食管炎的愈合情况进行对比分析。结果两组患者治疗后,实验组患者的总有效率(92.38%)明显大于对照组患者的总有效率(60.86%),差异有统计学意义(P<0.05);实验组患者的总治愈率(88.09%)明显高于对照组患者的总治愈率(58.69%),差异有统计学意义(P<0.05)。结论埃索美拉唑联合莫沙必利治疗反流性食管炎的临床疗效更为显著,较明显治愈了食管炎,临床上可以广泛应用。
Objective To investigate the clinical efficacy of mosapride combined with esomeprazole in the treatment of reflux esophagitis. Methods A total of 184 patients with reflux esophagitis treated in our hospital were selected and divided into experimental group and control group. The patients in control group and experimental group were treated with omeprazole and mosapride, Somolazole combined with mosapride treatment, the two groups of patients with clinical efficacy and healing of esophagitis comparative analysis. Results After treatment, the total effective rate (92.38%) in the experimental group was significantly higher than that in the control group (60.86%), the difference was statistically significant (P <0.05); the total cure rate in the experimental group (88.09%) was significantly higher than the control group (58.69%), the difference was statistically significant (P <0.05). Conclusion Esomeprazole combined with mosapride in the treatment of reflux esophagitis clinical efficacy is more significant, more obvious cure esophagitis, clinically applicable.